For Inflectra® (infliximab) Prescribing Information for Great Britain click here.
Adverse event reporting information can be found at the bottom of the page.
NOR-SWITCH was a randomised, double-blind, non-inferiority parallel-group study that compared the effect of switching from Remicade®† to Inflectra/CT-P13* (infliximab) in 481 patients across all indications.§1
There was a similar adverse event profile in stable patients switching from Remicade®† to CT-P13*, compared with those remaining on Remicade®.§1
Safety population. Data are number of events/number of patients (%).
Created from Jørgensen KK, et al. 2017.
Learn about the safety profile of Inflectra in patients with Crohn’s disease
Learn more
Learn more about TDM and biomarkers
Find out more
GONCZI L et al
Study 3.4
NOR-SWITCH safety
NOR-SWITCH efficacy
PROSIT-BIO safety
PROSIT-BIO efficacy
PROSIT-BIO study design
Switch studies
Paediatric studies
Induction & Maintenance
Inflammatory bowel disease
The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.
** This is an optional area where footnotes can live.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?